[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

El-Bagoury et al., 2013 - Google Patents

Evaluation of inactivated Rift Valley fever vaccine with paraffin oil adjuvant

El-Bagoury et al., 2013

View PDF
Document ID
17684168078455637476
Author
El-Bagoury G
El-Habbaa A
Ibrahim A
Noha E
Publication year
Publication venue
Benha Vet. Med. J

External Links

Snippet

ABSTRACT Rift Valley Fever (RVF) caused by an arbo-virus belonged to genus Phlebovirus, family Bunyaviridae, is an acute, febrile disease of ruminants. In Egypt, immunization of susceptible animals occurs using a locally prepared inactivated vaccine …
Continue reading at fvtm.stafpu.bu.edu.eg (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviradae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Similar Documents

Publication Publication Date Title
Monath et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity
Lodmell et al. DNA immunization protects nonhuman primates against rabies virus
Park et al. Enhanced immune responses of foot-and-mouth disease vaccine using new oil/gel adjuvant mixtures in pigs and goats
Jiang et al. Immunogenicity of a thermally inactivated rotavirus vaccine in mice
DK162421B (en) DOG COURSE VACCINE, PROCEDURES FOR PRODUCING IT AND VIRUS STEMS FOR USING THE VACCINE
Martin et al. Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB
Di Emidio et al. Efficacy and safety studies on an inactivated vaccine against bluetongue virus serotype 2
Starodubova et al. Rabies vaccines: Current status and prospects for development
Luo et al. Two potential recombinant rabies vaccines expressing canine parvovirus virion protein 2 induce immunogenicity to canine parvovirus and rabies virus
MX2007008836A (en) Improved vaccine against feline calicivirus.
RU2593718C1 (en) Inactivated emulsion vaccine against foot-and-mouth disease types a, o, asia-1
Ronchi et al. Preliminary results on innocuity and immunogenicity of an inactivated vaccine against Peste des petits ruminants.
US20180008699A1 (en) Vaccines for porcine epidemic diarrhea virus infections
RU2699671C1 (en) Vaccine for early protection against foot-and-mouth disease of type o inactivated emulsion
RU2665849C1 (en) Inactivated emulsion vaccine against foot-and-mouth disease type o
El-Bagoury et al. Evaluation of an inactivated combined oil vaccine prepared for foot and mouth disease and bovine ephemeral fever viruses
CN107326012A (en) A kind of cell line and its application
El-Bagoury et al. Evaluation of inactivated Rift Valley fever vaccine with paraffin oil adjuvant
Soliman et al. Effect of different inactivators on the efficacy of Egyptian foot and mouth disease SAT2 vaccine
TW201125579A (en) Heterologous prime-boost immunization regimen
Eladawy et al. Evaluation of formaldehyde and binary ethylenimine inactivated Newcastle disease virus vaccine from new isolate compared with imported NDV vaccine
Amin et al. The efficacy of FMD vaccine prepared from recently isolated FMD virus using Ictyolane 18 oil adjuvant
Rafique et al. Adaptation of Foot and Mouth Disease Virus Subtypes Pan Asia-II, Tur-06 and Sindh-08 towards the Vaccine Development and Serological Findings by SPC ELISA and Serum Neutralization Test
Kasem et al. Evaluation of the efficacy of simultaneous vaccination of cattle against rabies and foot and mouth disease viruses
El-Bagoury et al. Efficacy of inactivated BEF vaccine adjuvant with Montanide ISA 206 compared with the locally prepared inactivated BEF vaccines